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a b s t r a c t 
Purpose: Cerebral amyloid angiopathy (CAA) is a cerebral small vessel disease associated with perivascular 
𝛽-amyloid deposition. CAA is also associated with strokes due to lobar intracerebral haemorrhage (ICH). 18 F- 
flutemetamol amyloid ligand PET may improve the early detection of CAA. We performed pharmacokinetic 
modelling using both full (0–30, 90–120 min) and reduced (30 min) 18 F-flutemetamol PET-MR acquisitions, 
to investigate regional cerebral perfusion and amyloid deposition in ICH patients. 
Methods: Dynamic 18 F-flutemetamol PET-MR was performed in a pilot cohort of sixteen ICH participants; eight 
lobar ICH cases with probable CAA and eight deep ICH patients. A model-based input function (mIF) method 
was developed for compartmental modelling. mIF 1-tissue (1-TC) and 2-tissue (2-TC) compartmental modelling, 
reference tissue models and standardized uptake value ratios were assessed in the setting of probable CAA detec- 
tion. 
Results: The mIF 1-TC model detected perfusion deficits and 18 F-flutemetamol uptake in cases with probable 
CAA versus deep ICH patients, in both full and reduced PET acquisition time (all P < 0.05). In the reduced PET 
acquisition, mIF 1-TC modelling reached the highest sensitivity and specificity in detecting perfusion deficits 
(0.87, 0.77) and 18 F-flutemetamol uptake (0.83, 0.71) in cases with probable CAA. Overall, 52 and 48 out of 
the 64 brain areas with 18 F-flutemetamol-determined amyloid deposition showed reduced perfusion for 1-TC and 
2-TC models, respectively. 
Conclusion: Pharmacokinetic (1-TC) modelling using a 30 min PET-MR time frame detected impaired haemody- 
namics and increased amyloid load in probable CAA. Perfusion deficits and amyloid burden co-existed within 
cases with CAA, demonstrating a distinct imaging pattern which may have merit in elucidating the pathophysi- 
ological process of CAA. 
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IF population-based IF 
IF model-based IF 
. Introduction 
Cerebral amyloid angiopathy (CAA) is a cerebral small vessel disease
haracterised by the deposition of 𝛽-amyloid protein in cortical and lep-
omeningeal arterial walls, which is common in healthy elderly and in∗ Corresponding author. 
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053-8119/© 2020 The Author(s). Published by Elsevier Inc. This is an open access aeople with dementia ( Neuropathology Group, 2001 ). CAA is usually as-
ociated with stroke that is due to lobar rather than deep intracerebral
aemorrhage (ICH) ( Samarasekera et al., 2012 ), being present in 58% of
atients with lobar ICH ( Rodrigues et al., 2018 ). The modified Boston
riteria are the current in vivo reference standard for CAA diagnosis,
hich use the presence of multiple sites of macro-haemorrhage, micro-
leeds, and/or cortical superficial siderosis on susceptibility-weighted
SWI) magnetic resonance imaging (MRI) to categorise a patient as prob-
ble, possible or no CAA ( Linn et al., 2010 ). However, haemorrhages
ay represent the late consequences of advanced CAA, therefore pa-asiou). 
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o  ients with mild CAA before haemorrhage occurs, may not be identified
n MRI. 
Recent studies showed that amyloid-positron emission tomogra-
hy (PET) can differentiate probable CAA from healthy elderly and
atients with deep ICH, which is generally due to hypertension
 Charidimou et al., 2017 , 2018 ). However, another study did not show a
ifference in amyloid-PET uptake between patients with probable CAA
nd healthy controls ( Baron et al., 2014 ). Furthermore, as amyloid-
ET detects both perivascular and parenchymal 𝛽-amyloid, it may re-
ect CAA and/or Alzheimer’s disease (AD) ( Charidimou et al., 2017 ,
018 ). A recent study assessed a surrogate measure of cerebral perfu-
ion using standardised uptake value ratios (SUVR) analysis from an
arly phase 11 C-Pittsburgh compound B ( 11 C-PiB) time frame, reporting
educed SUVR in participants with probable CAA against age-matched
ontrols ( Farid et al., 2015 ). The same study showed lower SUVR occipi-
al/posterior cingulate ratios in participants with probable CAA against
 small cohort of AD patients ( Farid et al., 2015 ). There is no work
omparing absolute cerebral perfusion in probable CAA against deep
CH patients. Whether any increases in the amyloid-PET uptake may be
ssociated with cerebral perfusion differences in a distinct pattern in
robable CAA, is also currently unknown. 
18 F-flutemetamol is among the newer longer-lived amyloid-PET lig-
nds, which has recently gained regulatory approval for the assess-
ent of 𝛽-amyloid protein in AD ( Wolk et al., 2018 ; Zwan et al., 2017 ;
elissen et al., 2009 ; Heurling et al., 2015 ). 18 F-flutemetamol PET
ay enable the early detection of perivascular 𝛽-amyloid in CAA, ver-
us the current clinical standard MRI biomarkers ( Samarasekera et al.,
012 ). Nelissen et al. were the first to perform fully quantitative anal-
sis from PET-computed tomography (CT) 18 F-flutemetamol data in a
mall cohort of six patients, demonstrating significant correlations in
issue uptake estimates between a reversible 2-tissue compartmental (2-
C) model versus Logan graphical analysis ( Nelissen et al., 2009 ). In a
ollow-up study, Heurling et al. showed strong correlations in tissue up-
ake estimates derived using reference tissue models and SUVR versus
he 2-TC model ( Heurling et al., 2015 ). For both studies, the applied
canning window for dynamic imaging was 0–90 min ( Nelissen et al.,
009 ; Heurling et al., 2015 ). Minimising PET acquisition time for dy-
amic acquisitions would be clinically important, as it would reduce
atient discomfort and increase scanner availability whilst maintaining
uantitative accuracy. Beyond these studies assessing correlations in AD,
he pharmacokinetics of 18 F-flutemetamol in the presence of CAA using
ET-MRI have not been examined. In addition, it is unknown whether
inetic model estimates extracted from reduced PET acquisition time
rames ( < 90 min) can robustly detect CAA. 
Fully quantitative compartmental models in PET allow for both per-
usion and tracer uptake estimates, simultaneously in the tissue of in-
erest ( Gunn et al., 2001 ). However, compartmental modelling requires
 continuous metabolite-corrected (arterial) plasma input function (IF),
nd to measure this, repeated arterial sampling is needed throughout
ET imaging ( Nelissen et al., 2009 ; Heurling et al., 2015 ; Gunn et al.,
001 ). Arterial sampling is an invasive, labour-intensive procedure that
ncreases patient discomfort ( Boellaard et al., 2001 ; Eriksson et al.,
995 ). To avoid arterial sampling, reference tissue compartmental mod-
ls were developed which incorporate an indirect input function from
 reference tissue devoid of tracer-specific receptors or accumulation of
roteins ( Lammertsma and Hume, 1996 ; Lammertsma et al., 1996 ). A
etabolite corrected population-based IF (pIF) from another PET study
nvolving the same tracer can also be used, although pIF methods com-
only require a relatively large number of patient-derived IF inputs to
btain a representative input function ( Zanotti-Fregonara et al., 2013 ;
issanen et al., 2015 ). A model-derived IF (mIF) proposed by Cunning-
am et al. was based on adopting the basic 1-tissue (1-TC) model using
inetic information from a reference tissue, to yield an expression for
 patient-specific IF ( Cunningham et al., 1991 ). Although introduced
n simulation studies analysing neurotransmitter kinetics ( Morris et al.,p  005 ; Normandin and Morris, 2008 ), this mIF has not been examined
n compartmental modelling of 18 F-flutemetamol clinical data. 
In this work, we investigated whether perfusion deficits and 18 F-
utemetamol uptake are associated with probable CAA lobar ICH cases
ersus patients with deep ICH. To investigate whether this information
an be extracted using a simplified PET protocol, we examined perfusion
eficits and 18 F-flutemetamol uptake using both a full (consisted of two
eparate dynamic phases acquired at 0–30 min and 90–120 min post-
njection, respectively) and a reduced (30 min) PET-MR acquisition time
rame. In that context, we devised a mIF method to perform 1-TC and
-TC compartmental modelling which was compared against reference
issue models and SUVR in the setting of differentiating probable CAA
obar ICH cases from patients with deep ICH. 
. Materials and methods 
.1. Population and study design 
Sixteen patients with recent stroke due to ICH in the NHS Lothian
ealth Board region of Scotland were recruited for 18 F-flutemetamol
ET-MR imaging from the ongoing LINCHPIN study, which is a
ommunity-based inception cohort study of adults with spontaneous
CH, resident in NHS Lothian ( Rodrigues et al., 2018 ). All participants
eceived 18 F-flutemetamol PET-MR imaging 6–12 months after ICH
hen stable. Cognitive assessments were performed for all participants
rior to PET-MR imaging, using the mini mental state examination, the
ontreal cognitive assessment and Addenbrooke’s cognitive assessment
ests. 
Exclusion criteria included a known history of dementia, an ICH
econdary to an underlying cause other than cerebral small vessel dis-
ase (e.g. underlying tumour, intracranial vascular malformation, ve-
ous thrombosis, prior trauma or haemorrhagic conversion of a cerebral
nfarct) and contraindications to MRI. The study was performed with the
pproval of the Scotland A Research Ethics Committee, in accordance
ith the Declaration of Helsinki and with the written informed consent
f all patients. 18 F-flutemetamol was produced according to good man-
facturing practice guidelines (EudraLex, volume 4) at the Edinburgh
maging-QMRI radiochemistry laboratories of the University of Edin-
urgh, using a GE Healthcare PETtrace8 cyclotron. 
. PET-MR data acquisition 
18 F-flutemetamol brain PET-MR imaging was performed using a
ybrid 3T mMR Biograph system (Siemens Medical Solutions, Erlan-
en, Germany). Dynamic PET acquisition started at the time of intra-
enous injection of a target dose of 185 MBq (184.2 ± 6.2 MBq) 18 F-
utemetamol and lasted for 30 min in 3D list mode (phase 1). A second
eriod of 30 min PET data acquisition was repeated at 90 min post 18 F-
utemetamol injection to 120 min (phase 2). 
Before the start of each PET phase (1 and 2), a separate MR attenu-
tion correction map was acquired using the manufacturer’s ultrashort
cho time sequence. The following MRI sequences were performed dur-
ng PET phase 1: 3D T 1 -weighted, T 2 -weighted, fluid-attenuated inver-
ion recovery (FLAIR) and SWI sequences; PET phase 2: 3D T 1 -weighted,
 2 -weighted, FLAIR, T 2 
∗ -weighted gradient recalled echo and diffu-
ion tensor imaging. For the MR attenuation correction ultrashort echo
ime and the 3D T 1 -weighted (used for image reconstruction and im-
ge processing respectively), the pulse sequence details were: repetition
ime/echo time 11.90 ms/2.46 ms, flip angle 10°, 192 × 192 matrix,
00 × 300 field-of-view, number of echoes 2; repetition time/echo time
300 ms/2.98 ms, flip angle 9°, inversion time 1100 ms, 256 × 256
atrix, 256 × 256 field-of-view, respectively. 
Dynamic 18 F-flutemetamol PET scans were reconstructed into 16
rames over phase 1 (4 × 30, 6 × 60, 4 × 180, 2 × 300 s) and 11 frames
ver phase 2 (5 × 60, 2 × 150, 4 × 300 s), using a Ordered Subsets Ex-
ectation Maximisation reconstruction algorithm with 3 iterations, 21
G. Papanastasiou, M.A. Rodrigues, C. Wang et al. NeuroImage 225 (2021) 117482 
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Fig. 1. (a) 1-tissue compartmental (1-TC) and (b) 2-tissue compartmental (2- 
TC) model illustrations. C P , C T , C ND and C S are the concentrations of non- 
metabolised tracer in the arterial plasma, total concentration of tracer in the 
tissue, non-displaceable tracer in tissue and specifically bound tracer in the tis- 
sue, respectively. K 1 -k 4 are the rate constants. (c) Exchange of radioactivity con- 
centration with rate constants K 1 ́and k 2 ́, between the C P and the concentration 
of tracer in the reference region (devoid of specific binding) C R . 
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e  ubsets, 127 axial slices, 344 × 344 matrix, 2.09 × 2.09 × 2.00 mm pixels
nd 2 mm Gaussian filter, using the ultrashort echo time MR sequence
or attenuation correction. The reconstruction included corrections for
andoms, dead time and scatter. For PET phases 1 and 2, the voxel val-
es of all frames were decay-corrected to the time of 18 F-flutemetamol
dministration. 
. Patient diagnosis 
A neuroradiologist assessed the SWI MR data using the Syngo Via
oftware (Siemens Medical Solutions, Erlangen, Germany) to categorise
articipants as probable CAA or no CAA as defined by the modified
oston criteria ( Linn et al., 2010 ), masked to the clinical and 18 F-
utemetamol PET data. The size of ICH was measured using the Syngo
ia software. 
According to these criteria, patients with two or more haemorrhagic
oci (macrohaemorrhage, microbleed or cortical superficial siderosis) re-
tricted to lobar, cortical or cortical-subcortical regions, were classified
s probable CAA. Patients with deep ICH (non-lobar haemorrhage in the
odified Boston criteria), were classified as neither probable or possi-
le CAA (no CAA) ( Linn et al., 2010 ). This assessment was used as the
eference standard technique to evaluate quantitative 18 F-flutemetamol
ata analysis. 
. Visual assessments from 18 F-flutemetamol PET-MR data 
Two neuroradiologists (MR and GT) who had completed the
izamyl TM ( 18 F-flutemetamol) Electronic Training Programme indepen-
ently, rated the 18 F-flutemetamol uptake on the decay corrected PET
mages of phase 2 (derived from the 90 to 120 min post-injection inter-
al) fused to the participant’s 3D T 1 -weighted images, using the Syngo
ia software. Scans were classified as 18 F-flutemetamol positive over-
ll, if there was at least one positive region. In the absence of positive
egions, scans were classified as negative. In the event of disagreement,
he images were reviewed together and a consensus was reached. The
onsensus decision for overall positive/negative classification was used
o determine 18 F-flutemetamol PET positivity/negativity. 
. Image analysis 
To derive time-activity curves (TAC) and SUVR from the PET data
cross all brain regions, PET-MR co-registration and segmentation was
erformed using dedicated software (PMOD 3.8, Switzerland). Firstly,
he 3D T 1 -weighted MR data acquired in phases 1 and 2 were each
patially registered to a T 1 -weighted Montreal Neurological Institute
MNI) brain template (via non-linear registration). The transformation
atrix from the previous non-linear registration step was saved and
hen used to register (the dynamic and static) PET data to the regis-
ered (to the MNI template) 3D T 1 -weighted data. Tissue probability
aps were generated on the co-registered 3D T 1 -weighted data based on
he tissue probability map operation of SPM8 incorporated into PMOD
 Ashburner and Friston, 2005 ), which were then used to extract TAC
nd SUVR from the cortical areas. 
Based on the MNI template, standard volumes of interest (VOIs) were
efined on the co-registered PET images using automated anatomical
abelling in PMOD for 9 brain regions: the left and right frontal, pari-
tal, temporal, occipital lobes, and the cerebellar cortex. Tissue quantifi-
ation (perfusion-dependant and tracer uptake) comparisons were per-
ormed on TAC and SUVR extracted from the 8 cortical VOIs (target
issue) across all subjects. The cerebellar cortex TAC (reference tissue)
xtracted from each participant was used for the estimation of the mIF
in Eq. (5) ) and as the reference tissue for the SRTM and FRTM analy-
is. Co-registration and VOI segmentation were performed separately in
hases 1 and 2. 
To interpolate regional brain uptake between phases 1 and 2, a bi-
xponential function was fitted to all TAC in Matlab (MathWorks Inc.,atick, MA) as described by Nelissen et al. (2009 ): 
𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 = 𝜑 1 𝑒 − 𝜃1 𝑡 + 𝜑 2 𝑒 − 𝜃2 𝑡 (1)
Note that the second term of Eq. (1) was allowed to tend to 0 (using
he standard fittype Matlab function) when interpolation was approach-
ng mono-exponential decays. 
. Model-based plasma input function 
To measure an accurate metabolite-corrected IF required for 1-TC
nd 2-TC modelling in PET, arterial sampling is required to accurately
easure arterial plasma radioactivity concentration ( Gunn et al., 2001 ;
oellaard et al., 2001 ; Eriksson et al., 1995 ). 
The 1-TC model can be described by ( Fig. 1 a): 
 C T ( t ) ∕ dt = K 1 C P ( t ) − k 2 C T ( t ) (2)
here C P (t), C T (t) are the radioactivity concentrations from the arterial
lasma and target tissue and K 1 (influx constant of tracer from arterial
lasma into the tissue), k 2 (efflux constant of tracer from tissue into the
rterial plasma), are the rate constants. 
The 2-TC model can be described by the following set of equations
 Fig. 1 b): 
 C ND ( t ) ∕ dt = K 1 C P ( t ) − ( k 2 + k 3 ) C ND ( t ) + k 4 C S ( t ) 
 C S ( t ) ∕ dt = k 3 C ND ( t ) − k 4 C S ( t ) (3)
here C ND (t) and C S (t) are the radioactivity concentrations from the
on-displaceable tracer and specifically bound tracer (separate compart-
ents within the target tissue) and K 1 -k 4 are the rate constants. 
To avoid arterial sampling, reference tissue compartmental models
ere designed in which the arterial plasma IF C P (t) was substituted by
n indirect IF (TAC) from a reference tissue region devoid of recep-
ors that bind with the PET radiotracer ( Lammertsma and Hume, 1996 ;
ammertsma et al., 1996 ). 
The following relationship is satisfied and incorporated into the ref-
rence tissue compartmental models, describing the influx and efflux
G. Papanastasiou, M.A. Rodrigues, C. Wang et al. NeuroImage 225 (2021) 117482 
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w  f radioactivity concentration from the arterial plasma to the reference
issue ( Fig. 1 c): 
 C R ( t ) ∕ dt = K 1 ′C P ( t ) − k 2 ′C R ( t ) (4)
here C R (t) is the radioactivity concentration from the reference tissue
nd K 1 ′, k 2 ′ are the rate constants. Solving Eq. (4) for C R and by replac-
ng the uptake rate constants K 1 and K 1 ′ with their ratio R 1 ( = K 1 /K 1 ′)
o reduce the fitted parameters, C P can be eliminated from the refer-
nce tissue compartmental modelling process, as previously described
 Lammertsma and Hume, 1996 ; Lammertsma et al., 1996 ). 
In our implementation, Eq. (4) can be re-written as
 Cunningham et al., 1991 ): 
 P ( t ) = 
1 
K 1 ′
[ 
d C R ( t ) 
dt 
+ k 2 ′C R ( t ) 
] 
(5)
Assuming that a) the PET radioactivity in the C R (t) represents the
on-displaceable tracer in the cerebellar grey matter (reference tissue)
egion C R (t), b) there is no intermediate compartment between C P (t) and
 R (t), and c) that 
18 F-flutemetamol metabolites are polar molecules not
ble to cross the blood-brain-barrier ( Normandin and Morris, 2008 ), the
 P (t) can be modelled using Eq. (5) . 
In our mIF method, we used the TAC from the cerebellar grey matter
egion C R (t) of each patient, to derive an analytical expression for C P (t)
er patient. To derive the derivative in Eq. (3) , the C R (t) was differenti-
ted with respect to time. In Eq. (5) , the only unknown values were the
nflux and efflux constants K 1 ′and k 2 ′. 
K 1 ′and k 2 ′ were estimated by performing metabolite-corrected pIF-
ased 1-TC compartmental modelling ( Fig. 1 ). The pIF was derived from
 small cohort of six patients ( Heurling et al., 2015 ). To avoid any bias
n the per patient estimation of K 1 ′and k 2 ′ that can be introduced by
sing a small cohort-derived pIF ( Zanotti-Fregonara et al., 2013 ), pIF-
ased 1-TC-measured K 1 ′and k 2 ′ across all patients were averaged and
sed as inputs in Eq. (5) . It is important to note that the overall shape
f the mIF is determined by the mean K 1 ′and k 2 ′ values measured, the
ate of change of C R (t) (estimated by the time derivative) and the C R (t)
urve: 
 P ( t ) = f 
( 
mean K ′1 , mean k 
′
2 , 
d C R ( t ) 
dt 
, C R ( t ) 
) 
(6)
This step allowed extraction of a metabolite free mIF per patient,
hich was used to evaluate the ability of 1-TC and 2-TC modelling in
etecting probable CAA against deep ICH patients. 
. Quantitative analysis 
Kinetic model analysis was performed using customised in-house
oftware developed in Matlab. The code will be made available at
 https://github.com/Georgerun/NeuroKinModel ). The following steps
ere followed to measure mIF: 
1 1-TC modelling was initially performed in the cerebellar cortex
(used as the reference tissue) of all participants using a metabolite-
corrected pIF derived from a small cohort of six patients: three
healthy controls and three AD patients from a previous 18 F-
flutemetamol PET study ( Nelissen et al., 2009 ; Heurling et al., 2015 ).
This step allowed to extract K 1 ′and k 2 ′ estimates across all subjects.
2 To reduce any bias that can be introduced by using a small cohort-
derived pIF, K 1 ′and k 2 ′ estimates across all sixteen subjects were
averaged and mean K 1 ′and mean k 2 ′ were estimated. 
3 Mean K 1 ′and k 2 ′ values, the C R (t) curve from each subject (extracted
from the cerebellar cortex VOI) and the rate of change of C R (t) (esti-
mated by the time derivative) were then used in Eq. (5) to determine
the mIF for each subject. 
1-TC and 2-TC modelling was subsequently performed using the mIF
stimated for each patient. Implementing mIF, 1-TC and 2-TC-derivedinetic model estimates were assessed for their ability in detecting pa-
ients with probable CAA against patients with deep ICH, across 3 dif-
erent PET acquisition time frames: a) an interpolated 120 min (phase
 + 60 min interpolated phase + phase 2), b) concatenated 120 min
phase 1 + phase 2) and c) a 30 min (phase 1) PET acquisition. All
ACs were also analysed using the simplified reference tissue model
SRTM) ( Lammertsma and Hume, 1996 ) and the full reference tissue
odel (FRTM) ( Lammertsma et al., 1996 ), across all 3 PET acquisition
ime frames. SUVR analysis was extracted from phase 2. 
For each cortical VOI region, perfusion assessments were based on
he uptake rate constant K 1 (in mL/min/mL of tissue; for input function
ompartmental models) which describes the delivery of tracer from the
rterial plasma to the brain and reflects cerebral perfusion, or the rel-
tive perfusion estimate R 1 (for reference tissue models) ( Gunn et al.,
001 ). For all kinetic models, the k 2 estimate (min 
− 1 ) was also assessed
nd presented. The tracer specific binding was estimated either as the
olume of distribution in each target region V T (for 1-TC and 2-TC),
r through the binding potential (BP ND , as one of the fitted parameters
n SRTM, or as the ratio of fitted parameters k 3 /k 4 in FRTM models)
 Heurling et al., 2015 ; Lammertsma and Hume, 1996 ; Koopman et al.,
018 ). For reference tissue modelling and SUVR, the cerebellar cor-
ex was used as reference tissue throughout ( Nelissen et al., 2009 ;
eurling et al., 2015 ; Lin et al., 2016 ; Hsiao et al., 2012 ; Rodriguez-
ieitez et al., 2016 ; Rostomian et al., 2011 ). 
. Statistical analysis 
Dedicated software was used for statistical analysis (R Foundation
or statistical computing, Vienna, Austria; MedCalc Software, Ostend,
elgium). Pearson correlation tests were performed to assess correla-
ions and Bland Altman plot analysis was used to investigate systematic
ias in kinetic model estimates, derived from reduced (30 min) against
ull interpolated and concatenated (0–30, 90–120 min) PET acquisition
ime frames. Box and whisker plots investigated differences in K 1 and
 T between cases with probable CAA and deep ICH patients. Statistical
ifferences in perfusion-dependant (K 1 , R 1 ), k 2 and tracer uptake (V T ,
P ND and SUVR) estimates between probable CAA and deep ICH pa-
ients were assessed on a per cortical VOI region, using a two-sample
npaired t -test. 
Receiver-operating characteristic (ROC) analysis was used to deter-
ine threshold values for 1-TC and 2-TC model-measured perfusion-
ependant (K 1 ) and tracer uptake (V T ) estimates with the greatest sen-
itivity and specificity to detect probable CAA versus deep ICH (on a
er cortical VOI region). A Delong et al. nonparametric comparison
as used to compare the areas under the curve (AUC) of kinetic esti-
ates derived from reduced against full (interpolated) PET acquisitions
 DeLong et al., 1988 ). Model preference was assessed for the mIF 1-
C and 2-TC models (across all target tissue TACs) using the corrected
kaike Information Criterion (AICc). Statistical significance was defined
s two-sided P value < 0.05. 
0. Results 
0.1. Participants 
All baseline characteristics are presented in Table 1 . In total, sixteen
CH participants underwent PET-MR imaging and analysis, eight lobar
CH cases with probable CAA and eight deep ICH patients with no CAA
 Fig. 2 ) ( Linn et al., 2010 ). All participants were independent before the
CH (modified Rankin scale 0 or 1) and presented with relatively small
ymptomatic ICH (the median ICH volume was 4 cm 3 , with IQR 2–17).
Cases with probable CAA were slightly older compared with the deep
CH patients, although this difference did not reach statistical signifi-
ance. Cognition assessments were performed for all participants prior
o PET-MR imaging, to identify cases with probable CAA and patients
ith deep ICH with similar history of cognitive impairment, given that
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Table 1 
Baseline characteristics and visual assessments from the 18 F-flutemetamol data across all subjects. 
Baseline characteristics 
Lobar ICH with 
probable CAA cases 
( N = 8) 
Deep ICH patients ( N = 8) P value (where 
applicable) 
Age (years) 72 ± 8 68 ± 6 0.223 
Sex m/f 4/4 6/2 0.334 
ICH region Lobar Deep 
ICH location 
Basal ganglia 6 
Thalamus 2 
Frontal 3 
Occipital 2 
Parietal 1 
Temporal 2 
Hypertension 0 8 
Time between ICH and PET-MRI (days); median (IQR) 305 (240–350) 
Time between cognitive assessment and PET-MRI (days); 
median (IQR) 
41 (11–54) 
MMSE; median (IQR) 30 (29–30) 30 (30–30) 0.850 
MoCA; median (IQR) 28 (27–28) 26 (25–26) 0.084 
ACEIII; median (IQR) 97 (94–98) 95 (93–95) 0.139 
Visual assessment 
of the 
18 F-flutemetamol 
data 
Positive 7 0 < 0.001 
Negative 1 8 
ICH: intracerebral haemorrhage, IQR: interquartile range, MMSE = mini mental state examination, MoCA = Montreal cognitive assessment, 
ACEIII = Addenbrooke’s cognitive examination. 
Fig. 2. Fused PET-MR images (static: 90–120 min) of 18 F-flutemetamol uptake from a patient with deep ICH (a) and a patient with probable CAA (b). ICH: intracerebral 
haemorrhage, CAA: cerebral amyloid angiopathy. 
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o 1  his can be a confounder of the association between CAA and stroke
 Wolk et al., 2009 ). On cognition assessments, there were no significant
ifferences between cases with probable CAA and patients with deep
CH ( Table 1 ). All participants demonstrated normal cognitive functions
 Table 1 ) ( Wolk et al., 2009 ; Klunk et al., 2004 ). 
On visual assessments, 7 out 8 cases with probable CAA were classi-
ed as positive and all patients with deep ICH were classified as negative
or 18 F-flutemetamol uptake. 
1. Quantitative analysis from full PET-MR acquisition 
In total, 128 target tissue TACs were analysed (64 TACs from cases
ith probable CAA against 64 TACs from patients with deep ICH). Ini-
ially, 1-TC and 2-TC modelling was performed using the pIF from theull interpolated (0–30, 90–120 min) PET-MR data (mean values are
resented in the Supplementary file 1). The whole blood and metabo-
ite corrected pIF are illustrated in the Supplementary file 2. Significant
ifferences between cases with probable CAA and patients with deep
CH were only observed for the K 1 estimate for both models ( P < 0.01).
o significant differences were observed in K 1 ′and k 2 ′ estimates be-
ween 1-TC and 2-TC modelling, and between cases with probable CAA
nd patients with deep ICH for both models. The mean pIF 1-TC model-
erived K 1 ′and k 2 ′ estimates used to calculate the mIF are shown in the
upplementary file 1. 
Subsequently, 1-TC and 2-TC modelling was examined using the mIF
rom the full interpolated (0–30, 90–120 min) PET-MR data. Examples
f cerebellar cortex TACs and mIFs are presented in Fig. 3 . The K and
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Fig. 3. Reference tissue (cerebellar grey matter) time-activity curves in (a) and (b) were used to estimate model-based input functions for the same control (c) and 
patient with probable CAA (d), respectively. Dash-dotted line in (a) shows the reduced PET acquisition time frame (30 min) of dynamic curves examined throughout. 
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0   2 estimates were significantly lower for both models in probable CAA
ases against patients with deep ICH. The 1-TC-derived V T was signif-
cantly higher in probable CAA cases versus patients with deep ICH
 Table 2 ). Examples of 1-TC and 2-TC model fits are shown in the Sup-
lementary file 3. 
On box and whisker plots, the median and interquartile range (IQR)
alues for 1-TC and 2-TC-derived K 1 in cases with probable CAA and
eep ICH patients were 0.24 (0.22, 0.27) and 0.27 (0.25, 0.30); 0.25
0.23, 0.27) and 0.28 (0.25, 0.31), respectively ( Fig. 4 ). The median
nd IQR values for 1-TC and 2-TC-derived V T in cases with probable
AA and deep ICH patients were 2.88 (2.72, 3.08) and 2.74 (2.63, 2.88);
.10 (2.87, 3.48) and 3.12 (2.87, 3.43), respectively ( Fig. 4 ). 
SRTM and FRTM models were also investigated using the full inter-
olated (0–30, 90–120 min) data. Significant differences between cases
ith probable CAA and patients with deep ICH were only observed for
he R 1 and for the SRTM-derived k 2 estimates ( Table 2 ). 
To investigate whether the interpolated data can affect model esti-
ates, kinetic modelling was repeated using full concatenated (elimi-
ating interpolation) PET-MR data. Although significant differences be-
ween cases with probable CAA versus patients with deep ICH were
aintained in the full concatenated analysis, these were lower compared
o the full interpolated analysis across all models ( Table 2 ). 
SUVR analysis extracted from phase 2 was significantly higher
n cases with probable CAA versus patients with deep ICH (mean
UVR = 1.51 ± 0.26 vs 1.26 ± 0.16, respectively). 2. Quantitative analysis from reduced PET-MR acquisition 
Following full interpolated and concatenated PET-MR analysis,
uantitative analysis was investigated using a reduced (30 min; from
hase 1) acquisition time frame. Both the mIF 1-TC and 2-TC models
emonstrated significantly lower K 1 and k 2 estimates, and significantly
igher tracer uptake (V T ) estimates for probable CAA cases versus deep
CH patients, respectively ( Table 2 ). For the reference tissue models, sig-
ificant differences between probable CAA cases and deep ICH patients
ere only observed for the R 1 and for the SRTM-derived k 2 estimates. 
Correlations coefficients were investigated between kinetic model
nalysis derived from the reduced against full interpolated and concate-
ated PET-MR time frames (Supplementary file 4). All mIF and reference
issue models demonstrated significant, strong correlations in perfusion-
ependant estimates derived from the reduced against full interpolated
ata ( Fig. 5 ). Significant, strong correlations in tracer uptake estimates
rom reduced against full interpolated data were only observed for the
ase of the 1-TC model ( Fig. 6 ). On Bland Altman plot analysis, the sys-
ematic bias between reduced against full PET-MR analyses were low,
xcept for the 2-TC and FRTM-measured tracer uptake estimates ( Fig. 6 ,
upplementary file 4). 
On box and whisker plots, the median and IQR values for 1-TC and
-TC-derived K 1 in cases with probable CAA and deep ICH patients were
.25 (0.23, 0.26) and 0.28 (0.25, 0.31); 0.25 (0.23, 0.27) and 0.28 (0.26,
.31), respectively ( Fig. 4 ). The median and IQR values for 1-TC and 2-
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Table 2 
Mean (SD) kinetic model estimates measured using the model-based input function (mIF) and refer- 
ence tissue models, across all PET acquisition time frames examined. Perfusion (K 1 or R 1 ), k 2 and 
tracer uptake estimates (V T or BP ND ) for 1-TC, 2-TC, SRTM, FRTM models are presented, extracted 
from the 8 cortical VOIs (target tissue) across all subjects. The 8 cortical VOIs were the left and 
right frontal, parietal, temporal, occipital lobes (described in the Methods). Significant differences 
between cases with CAA and patients with deep ICH are denoted with ∗ , ∗ ∗ and † ( ∗ , ∗ ∗ and † show 
P < 0.05, P < 0.01 and P < 0.001, respectively). K 1 and V T are measured in mL/min/mL and mL/mL, 
respectively; R 1 , and BP ND are unitless quantities. The k 2 is measured in min 
− 1 . 
Acquisition frame/Model application mIF 1-TC mIF 2-TC SRTM FRTM 
120 min PET (interpolated dataset) 
K 1 /R 1 Probable CAA 0.25 (0.03) † 0.26 (0.03) † 0.91 (0.08) † 0.89 (0.07) † 
Deep ICH 0.29 (0.03) † 0.29 (0.03) † 1.00 (0.14) † 1.00 (0.14) † 
k 2 Probable CAA 0.09 (0.01) 
∗ ∗ 0.10 (0.01) ∗ ∗ 0.05 (0.05) ∗ ∗ 0.01 (0.04) 
Deep ICH 0.10 (0.01) ∗ ∗ 0.11 (0.01) ∗ ∗ 0.06 (0.08) ∗ ∗ 0.03 (0.06) 
V T /BP ND Probable CAA 2.89 (0.30) 
∗ ∗ 3.19 (0.48) 0.25 (0.35) 0.34 (0.67) 
Deep ICH 2.73 (0.16) ∗ ∗ 3.16 (0.49) 0.24 (0.44) 0.33 (0.45) 
120 min PET (concatenated dataset) 
K 1 /R 1 Probable CAA 0.29 (0.03) 
∗ 0.30 (0.03) ∗ 0.93 (0.06) ∗ 0.92 (0.06) ∗ 
Deep ICH 0.32 (0.03) ∗ 0.32 (0.03) ∗ 0.98 (0.08) ∗ 0.99 (0.11) ∗ 
k 2 Probable CAA 0.12 (0.01) 
∗ 0.12 (0.01) ∗ 0.07 (0.09) ∗ 0.03 (0.08) 
Deep ICH 0.13 (0.01) ∗ 0.13 (0.01) ∗ 0.14 (0.19) ∗ 0.03 (0.08) 
V T /BP ND Probable CAA 2.42 (0.16) 
∗ 2.41 (0.15) 0.24 (0.40) 0.47 (0.66) 
Deep ICH 2.35 (0.15) ∗ 2.37 (0.15) 0.23 (0.32) 0.45 (0.46) 
30 min PET 
K 1 /R 1 Probable CAA 0.25 (0.02) † 0.26 (0.02) † 0.93 (0.15) † 0.89 (0.08) † 
Deep ICH 0.30 (0.03) † 0.29 (0.03) † 0.99 (0.14) † 0.98 (0.11) † 
k 2 Probable CAA 0.09 (0.01) 
∗ ∗ 0.09 (0.01) ∗ ∗ 0.07 (0.09) ∗ ∗ 0.02 (0.04) 
Deep ICH 0.10 (0.01) ∗ ∗ 0.10 (0.01) ∗ ∗ 0.11 (0.19) ∗ ∗ 0.03 (0.05) 
V T /BP ND Probable CAA 2.84 (0.24) 
∗ ∗ 2.85 (0.34) ∗ ∗ 0.26 (0.45) 0.43 (0.56) 
Deep ICH 2.63 (0.16) ∗ ∗ 2.72 (0.20) ∗ ∗ 0.25 (0.46) 0.42 (0.59) 
ICH: intracerebral haemorrhage, SD: standard deviation, 1-TC: 1-tissue compartmental model, 2-TC: 
2-tissue compartmental model, SRTM: simplified reference tissue model, FRTM: full reference tissue 
model, VT: volume of distribution, BPND: binding potential. 
Fig. 4. Box and whisker plots demonstrating differences in K 1 (a, b) and V T (c, d) estimates between cases with CAA (red) and patients with deep ICH (blue), for 
model-based input function 1-TC and 2-TC modelling. Model analysis from reduced (30 min) versus interpolated full (120 min) PET acquisition is shown. Significant 
differences between cases with CAA and controls for each model are denoted with ∗ ∗ (when P < 0.01) and † (when P < 0.001). CAA: cerebral amyloid angiopathy, 
1-TC: 1-tissue compartment model, 2-TC: 2-tissue compartment model, ICH: intracerebral haemorrhage. 
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Fig. 5. Scatter plots with correlation coefficients (a, b) and Bland Altman plots (c, d) for 1-TC and 2-TC model-derived perfusion-dependant estimate K 1 , in reduced 
versus full interpolated PET acquisition. 1-TC: 1-tissue compartment, 2-TC: 2-tissue compartment. 
Table 3 
Results from ROC analysis are presented. Parentheses show (95% confidence intervals). Statistically 
significant areas under the curve are shown with ∗ ∗ and † ( ∗ ∗ and † show P < 0.01 and P < 0.001, 
respectively). K 1 and V T are measured in mL/min/mL and mL/mL, respectively. 
Statistical 
analysis/Model 
1-tissue compartment 2-tissue compartment 
Reduced (30 min) Full IN (120 min) Reduced (30 min) Full IN (120 min) 
Areas under the Curve (AUC) 
K 1 0.87 (0.80, 0.93) † 0.88 (0.81, 0.95) † 0.83 (0.75, 0.91) † 0.81 (0.72, 0.90) † 
V T 0.84 (0.77, 0.91) 
∗ ∗ 0.84 (0.76, 0.92) ∗ ∗ 0.76 (0.66, 0.86) ∗ ∗ 0.54 (0.43, 0.65) 
Thresholds on ROC analysis 
K 1 < 0.26 < 0.26 < 0.27 < 0.29 
V T > 2.62 > 2.73 > 2.75 > 3.06 
Sensitivity and Specificity 
Sensitivity (K 1 ) 0.87 (0.79, 0.95) 0.78 (0.68, 0.88) 0.85 (0.73, 0.97) 0.89 (0.78, 1.00) 
Specificity (K 1 ) 0.77 (0.64, 0.87) 0.81 (0.72, 0.90) 0.64 (0.53, 0.75) 0.67 (0.55, 0.79) 
Sensitivity (V T ) 0.83 (0.74, 0.92) 0.80 (0.69, 0.91) 0.83 (0.74, 0.92) 0.74 (0.60, 0.88) 
Specificity (V T ) 0.71 (0.59, 0.83) 0.73 (0.61, 0.85) 0.63 (0.50, 0.76) 0.48 (0.32, 0.64) 
VT: volume of distribution. 
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.86 (2.73, 3.02) and 2.67 (2.55, 2.80); 2.93 (2.69, 3.00) and 2.71 (2.56,
.82), respectively ( Fig. 4 ). 
On ROC analysis, high AUC were observed for both mIF compart-
ental model-measured K 1 and tracer uptake estimates ( Table 3 , Fig. 7 ).
he highest AUC for the detection of probable CAA cases against deep
CH patients was reached by the 1-TC model, across both the reduced
nd full interpolated PET-MR data analysis ( P < 0.01). There was a sig-ificant improvement in the AUC for the 2-TC-measured V T extracted
rom the reduced time frame against full interpolated PET-MR data anal-
sis. No other differences in AUC were observed between the reduced
nd full interpolated time frames. 
High concurrence of perfusion deficits and amyloid burden was ob-
erved for both 1-TC and 2-TC models, in the reduced time data analy-
is ( Table 4 , Fig. 7 ). Overall, 52 and 48 out of the 64 brain areas with
myloid deposition (V > thresholds identified on ROC; Table 3 ) showedT 
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Fig. 6. Scatter plots with correlation coefficients (a, b) and Bland Altman plots (c, d) for 1-TC and 2-TC model-derived volume of distribution V T , in reduced versus 
full interpolated PET acquisition. 
Table 4 
Co-occurrence of cerebral perfusion deficits in areas of increased amyloid load for patients with probable CAA and patients with deep 
ICH, per brain region ( N = 16 per brain region, e.g. left and right frontal times 8 patients) and total ( N = 64, for all brain regions across 
all lobes) per group (8 cases with probable CAA; 8 patients with deep ICH). Co-occurrence of perfusion deficits and amyloid burden was 
defined as both K 1 and V T estimates being lower and higher than ROC-identified thresholds for K 1 and V T (see Table 3 ) within a brain 
region, respectively. 
Model and PET-MR time frame/brain region ( N = 16) and total ( N = 64) 1-TC (30 min) 2-TC (30 min) 1-TC (120 min) 2-TC (120 min) 
Frontal- CAA 13 12 13 10 
Occipital- CAA 12 11 12 12 
Parietal- CAA 14 12 13 10 
Temporal- CAA 13 13 13 10 
Total- CAA 52 48 51 42 
Frontal- deep ICH 0 1 1 2 
Occipital- deep ICH 0 0 2 4 
Parietal- deep ICH 1 2 1 2 
Temporal- deep ICH 3 4 4 4 
Total- deep ICH 4 7 8 12 
ICH: intracerebral haemorrhage, 1-TC: 1-tissue compartmental model, 2-TC: 2-tissue compartmental model. The full interpolated 
(120 min) PET-MR time frame was assessed. 
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s  educed perfusion (K 1 < thresholds identified on ROC) for 1-TC and 2-TC
odels, respectively. This was also observed for the 1-TC model in the
ull interpolated data analysis. Using the reduced PET-MR time frame in
he full cohort, K 1 estimates in brain areas with amyloid burden were
ignificantly lower compared to areas without amyloid load ( P < 0.005,
or both models). 3. Quality of model fit 
On AICc, all brain regions showed a marginal preference for 1-TC
ersus 2-TC in the full interpolated PET (frontal: 53%, parietal: 52%,
emporal: 51%, occipital: 55%, in supplementary file 5). All regions
howed slightly stronger preference for 1-TC versus 2-TC in the reduced
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Fig. 7. ROC curves presenting sensitivity and specificity of mIF 1-TC and 2-TC modelling from reduced (RA-30 min; green line) versus full interpolated (FA-120 min; 
blue line) PET acquisition, in terms of identifying cases with probable CAA versus patients with deep ICH (and no CAA) classified using the modified Boston criteria. 
mIF: model-based input function, 1-TC: 1-tissue compartment, 2-TC: 2-tissue compartment, CAA: cerebral amyloid angiopathy, ICH: intracerebral haemorrhage. 
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S  frontal: 58%, parietal: 53%, temporal: 57%, occipital: 56%, in supple-
entary file 5) against the full interpolated PET, although this difference
etween models remained small. 
On visual inspection, no obvious differences were observed between
-TC and 2-TC model fits and both models were able to fit appropriately
he peak and the tail of all TAC. 
4. Discussion 
The main findings of this study demonstrated that PET compartmen-
al modelling reached high sensitivity and specificity for differentiating
obar ICH participants with probable CAA from deep ICH patients (clas-
ified using the modified Boston criteria) in a pilot cohort. Using the
IF method in 18 F-flutemetamol PET-MR data, the 1-TC model iden-
ified congruent perfusion impairments and amyloid accumulation in
articipants with probable CAA against patients with deep ICH, which
ere consistent in both the reduced versus the full interpolated PET-MR
ata analysis. 5. Cases with probable CAA against patients with deep ICH 
This is the first study assessing the sensitivity and specificity of com-
artmental models using a kinetic model-based input function method
rom dynamic PET-MR data, for the detection of probable CAA. We
howed that mIF 1-TC modelling consistently detected perfusion deficits
nd amyloid deposition in cases with probable CAA against patients
ith deep ICH. This is an important step towards rigorously investi-
ating whether perivascular 𝛽-amyloid is a distinct underlying pathol-
gy leading to stroke due to ICH, versus hypertension-associated pre-
umed arteriosclerosis and deep ICH ( Group, 2001 ; Samarasekera et al.,
012 ; Rodrigues et al., 2018 ; Linn et al., 2010 ; Charidimou et al., 2017 ;
haridimou et al., 2018 ). 
To our knowledge, we are also the first to investigate absolute per-
usion (with K 1 ; in mL/min/mL) and amyloid deposition in CAA, us-
ng 18 F-flutemetamol. Our analysis is in line with a recent study, in
hich a surrogate measure of cerebral perfusion was performed using
UVR analysis from an early phase (1–6 min) 11 C-PiB time frame, show-
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ng reduced SUVR in patients with probable CAA against age-matched
ontrols ( Farid et al., 2015 ). Other recent studies showed higher amy-
oid load in cases with CAA versus controls with deep ICH using ei-
her 11 C-PiB ( Tsai et al., 2017 ), or 18 F-florbetapir ( Gurol et al., 2016 ;
aposo et al., 2017 ) amyloid ligands. Our results ( Table 3 ) are compa-
able with a recent meta-analysis showing that the sensitivity and speci-
city of amyloid PET in detecting increased amyloid load in CAA was
n the range 0.60–0.91 and 0.56–0.90, respectively ( Charidimou et al.,
017 ). In our analysis, we demonstrated both differences in the 18 F-
utemetamol uptake, and impaired haemodynamics co-existing with
myloid burden in lobar ICH participants with probable CAA versus
eep ICH patients ( Tables 2-4 , Fig. 7 ). 
Previous studies examined associations between cerebral perfusion
nd hypo-metabolism in patients with dementia, using dual-tracer (amy-
oid ligand and 18 F-Fluorodeoxyglucose) protocols ( Lin et al., 2016 ;
siao et al., 2012 ; Rodriguez-Vieitez et al., 2016 ; Rostomian et al.,
011 ; Meyer et al., 2011 ; Fu et al., 2014 ). In these studies, a surro-
ate SUVR measure of cerebral perfusion was typically extracted from
arly phase time frames ( ≤ 1–6 min) of 18 F-florbetapir ( Lin et al.,
016 ; Hsiao et al., 2012 ), or 11 C-PiB data ( Rodriguez-Vieitez et al.,
016 ; Rostomian et al., 2011 ). In some cases, the SRTM-derived rela-
ive perfusion estimate (R 1 ) was assessed ( Hsiao et al., 2012 ; Rodriguez-
ieitez et al., 2016 ; Meyer et al., 2011 ). Although all these stud-
es showed strong correlations in the cerebral distribution of hypo-
erfusion and hypo-metabolism versus cognitive mini mental state ex-
mination scores ( Lin et al., 2016 ; Hsiao et al., 2012 ; Rodriguez-
ieitez et al., 2016 ; Rostomian et al., 2011 ; Meyer et al., 2011 ; Fu et al.,
014 ), weak or no associations between hypo-perfusion, amyloid load
nd cognitive scores were demonstrated in patients with dementia
 Lin et al., 2016 ; Meyer et al., 2011 ; Fu et al., 2014 ). Furthermore,
in et al. showed that in amnestic mild cognitive impairment, PET
myloid deposition occurs before the onset of perfusion deficits, and
n AD, hypo-perfusion and amyloid load follow different spatial tra-
ectories in the brain ( Lin et al., 2016 ). It is known that the current
myloid PET tracers (including 18 F-flutemetamol) show high affinity
o both parenchymal and perivascular 𝛽-amyloid ( Ni et al., 2013 ).
ence, there is currently no PET diagnostic method for differentiat-
ng CAA from AD ( Samarasekera et al., 2012 ; Charidimou et al., 2017 ;
haridimou et al., 2018 ; Farid et al., 2015 ). An interesting observation
n our data analysis is that the perfusion estimate K 1 showed higher sen-
itivity and specificity versus the V T in detecting cases with CAA ver-
us patients with deep ICH. Although impaired resting perfusion may
lso be observed in cases of hypertension-related small vessel disease
which can lead to deep ICH) ( Shi et al., 2016 ), our ROC results re-
ect the evident spatial extent of cerebral perfusion deficits in the pres-
nce of CAA. Demonstrating perfusion deficits and amyloid burden co-
xisting globally in non-demented cases with CAA is an important find-
ng, as it can contribute towards elucidating the exact mechanisms of
he presumed pathology (perivascular 𝛽-amyloid) against deep ICH, and
an be considered as a diagnostic tool to potentially differentiate CAA
gainst AD. 
On ROC analysis, perfusion deficits and amyloid accumulation were
ongruent in cases with probable CAA ( Fig. 7 , Tables 3-4 ). These per-
usion deficits and amyloid accumulation were both global within cases
ith probable CAA, which is consistent with the fact that CAA is a diffuse
isease affecting globally the cerebral vasculature ( Charidimou et al.,
018 ). It is known that up to about 20–30% of healthy elderly can
e 𝛽-amyloid positive on amyloid-PET imaging, due to incipient AD
 Charidimou et al., 2018 ; Mattsson et al., 2014 ; Bangen et al., 2017 ).
revious studies have reported perfusion decreases ( Mattsson et al.,
014 ), increases ( Bangen et al., 2017 ), or longitudinal increases and
ecreases ( Sojkova et al., 2008 ) in certain brain regions (of 𝛽-amyloid
ositive healthy elderly) that are associated with the onset of AD. These
onflicting perfusion results were attributed to either decreased brain
unction (reduced perfusion), or compensatory responses (increased per-
usion) to incipient AD ( Mattsson et al., 2014 ; Bangen et al., 2017 ;ojkova et al., 2008 ). On histopathology, patients with AD demon-
trate a high prevalence of CAA which is usually mild to moderate,
hilst in CAA with lobar ICH the underlying CAA pathology is se-
ere ( Charidimou et al., 2017 ; Charidimou et al., 2018 ). Following fur-
her assessments in larger patient cohorts, our imaging pattern can be
mportant for the early diagnosis (before haemorrhage occurs) of se-
ere CAA, against 𝛽-amyloid positive healthy elderly with incipient AD
 Charidimou et al., 2017 ; Charidimou et al., 2018 ; Mattsson et al., 2014 ;
angen et al., 2017 ; Sojkova et al., 2008 ). Moreover, our imaging pat-
ern defines the framework to investigate whether mild to moderate
AA can be efficiently distinguished against 𝛽-amyloid positive healthy
lderly with incipient AD. 
6. Reduced versus full analysis 
In the full interpolated and concatenated data analysis, all models
dentified perfusion deficits in cases with CAA versus patients with deep
CH. Unlike the 1-TC model, the diagnostic ability of the 2-TC model in
etecting amyloid load was possibly compromised due to the 60 min in-
erval between phases 1 and 2, in the interpolated data analysis. These
esults were similar in the concatenated data analysis, examined to as-
ess whether the interpolated data component could bias model perfor-
ance. 
We showed that mIF 1-TC- and 2-TC-derived V T from a 30 min PET-
R acquisition time can stratify brain areas with CAA vs deep ICH.
hese results were consistent with our visual assessments and SUVR
nalysis extracted from phase 2. Our reduced time SRTM analysis is
n line with a previous PET-MR study, which showed that the SRTM-
tted parameter BP ND is compromised when a 30 min is examined ver-
us a 60 min ( 18 F-florbetapir) acquisition in normal ageing subjects
 Scott et al., 2018 ). It is known that the K 1 /k 2 ratio and the k 3 -k 4 esti-
ates used to measure V T (1-TC-V T = K 1 /k 2 ; 2-TC-V T = K 1 /k 2 (1 + k 3 /k 4 ))
hould be independent of the K 1 perfusion-dependant estimates alone
 Gunn et al., 2001 ). As our K 1 (and k 2 ) estimates were significantly
ower in cases with probable CAA versus patients with deep ICH for
oth 1-TC and 2-TC models (across all time frames analysed), our re-
ults indicate that our V T estimates were independent of the K 1 estimates
lone. 
On AICc, all brain regions showed a marginal preference for 1-
C versus 2-TC in both full interpolated and reduced PET mIF analy-
is (supplementary file 5). This finding can indicate that either model
an be used to describe 18 F-flutemetamol kinetics in our data. Since
-TC involves additional fitted parameters versus 1-TC, a shorter in-
erval between phases 1 and 2 may be needed to stabilise model fit-
ing and potentially increase further its quality of fit and diagnos-
ic ability. Heeman et al. recently showed that a dual-phase proto-
ol (0–30 followed by a 90–110 min) may allow accurate estimation
f SRTM-derived BP ND when fitting SRTM-simulated 
18 F-flutemetamol
ACs ( Heeman et al., 2019 ). However, they also showed system-
tic bias in SRTM-derived 18 F-flutemetamol uptake when fitting 2-TC-
imulated TACs ( Heeman et al., 2019 ). Although 2-TC and SRTM have
oth been used to describe 18 F-flutemetamol kinetics ( Nelissen et al.,
009 ; Heurling et al., 2015 ), there is a clear discrepancy in their
odel architecture: the 2-TC describes the target tissue as having two-
ompartments, whilst the SRTM describes it as a single-compartment
such as the 1-TC; Fig. 1 ). Hence, based upon kinetic model principles,
he 1-TC (not yet extensively investigated in terms of 18 F-flutemetamol
ptake in the target tissue ( Nelissen et al., 2009 )) can also be used
s a simplified approach to describe 18 F-flutemetamol kinetics, with-
ut introducing additional assumptions needed for SRTM (such as that
on-specific binding is the same in the target and reference tissues)
 Lammertsma and Hume, 1996 ; Lammertsma et al., 1996 ). Note that as-
essing model performance using synthetic PET data is beyond the scope
f the current work, where we focused to assess whether mIF compart-
ental models can differentiate probable CAA patients from deep ICH
atients. 
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7. Model based input function 
In our mIF implementation, we adopted an alternative formula-
ion of the standard kinetic model Fig. 1 c, Eqs. (4) and (5) . Previous
odel-based IF approaches in clinical data have mainly used the si-
ultaneous estimation (SIME) approach, which attempts to estimate
F and kinetic parameters simultaneously from multiple brain regions
 Zanotti-Fregonara et al., 2011 ; Zanderigo et al., 2015 ). However, this
pproach requires at least one blood sample to be acquired during
ET imaging, and its test-retest reliability was recently found to be
ow ( Zanderigo et al., 2018 ). Compared to previous model-based IF ap-
roaches, our mIF method did not require arterial sampling and can
otentially be adapted to estimate metabolite corrected mIF using other
ET tracers (considering that a small cohort pIF is available to estimate
he K 1 ′and k 2 ′). 
8. Study limitations 
Our 1-TC and 2-TC modelling assessments were derived from a small
CH cohort. However, this is the first study demonstrating congruent
erfusion deficits and amyloid accumulation in a pilot cohort of cases
ith probable CAA versus patients with deep ICH. To calculate mIFs, we
xtracted mean pIF 1-TC model -derived K 1 ′and k 2 ′ estimates and we
lso assumed a single compartment within the reference tissue ( Eq. (4) ).
ur pIF was originally derived from a small cohort of three healthy
ontrols and three AD patients from a previous 18 F-flutemetamol PET
tudy ( Nelissen et al., 2009 ; Heurling et al., 2015 ) and therefore may
ot be able to represent actual input functions for some patients. This
an explain why pIF compartmental modelling did not detect differences
n amyloid load between probable CAA and deep ICH. However, using
ean pIF 1-TC model-derived K 1 ′and k 2 ′ values, we aimed to avoid bias
hat could have been introduced in K 1 ′and k 2 ′ values due to possible de-
iations of the pIF from the actual input functions, in some patients. Al-
hough it is standard for the cerebellum to be considered as a reference
issue devoid of 18 F-flutemetamol-specific receptors ( Heurling et al.,
015 ), a single compartment may not always suffice in cases of slow
on-specific retention ( Nelissen et al., 2009 ). Hence, our mIF method
ill benefit from validation in a future experiment involving arterial
ampling, to extensively assess the above assumptions. A small num-
er of late arterial samples would be useful to scale our pIF on a per
atient basis ( Zanotti-Fregonara et al., 2013 ; Rissanen et al., 2015 ). A
alidation experiment would also give access to realistic patient-specific
hole blood (non-metabolite corrected) curves, which may allow to re-
iably estimate the contribution of the fractional blood volume v b in our
IF estimation and compartmental models ( Lammertsma, 2002 ). The
deal reference standard for CAA diagnosis is a histopathological assess-
ent, although this is rarely performed in living participants ( Linn et al.,
010 ). Thus, we used the MR-based modified Boston criteria to classify
obar ICH participants with probable CAA versus deep ICH patients,
s this is the current in vivo reference standard for diagnosing CAA
 Linn et al., 2010 ; Charidimou et al., 2017 ; Charidimou et al., 2018 ).
e showed that our mIF compartmental modelling reached high sen-
itivity and specificity in detecting perfusion deficits and amyloid load
n CAA. We did not perform 15 O-water PET imaging to extract abso-
ute blood flow quantification. Although we previously showed that the
iagnostic performance of 15 O-water PET imaging depends on the quan-
ification technique used, it is considered the reference standard imag-
ng technique for perfusion assessments ( Papanastasiou et al., 2018 ).
ur model-derived K 1 alone demonstrated high sensitivity and speci-
city in detecting cases with CAA versus patients with deep ICH (across
oth 1-TC and 2-TC models). The 60 min interval between phases 1 and
 possibly reduced the diagnostic ability of 2-TC in detecting amyloid
oad. The 60 min interval between phases 1 and 2 has also to some ex-
ent affected the discriminatory ability of mIF 1-TC and 2-TC modelling
n the concatenated, compared to the interpolated data analysis used
o stabilise model fitting ( Table 2 ). A shorter interval may enhance theiscriminatory ability of compartmental modelling in the concatenated
ata analysis and may therefore help to avoid interpolation between
hases. In accordance with clinical practice, our imaging protocol was
esigned to reduce patient discomfort whilst accommodating additional
atient scans in between phases 1 and 2. 
9. Conclusions 
The mIF 1-TC model method for 18 F-flutemetamol PET-MR showed
he highest diagnostic ability in separately detecting impaired haemody-
amics and amyloid load in probable CAA, versus deep ICH. We demon-
trated that these findings can be reproduced using a reduced (30 min)
ET acquisition, which is potentially useful for simplifying PET imag-
ng protocols in the clinical setting compared to longer or dual-phase
pproaches. 
Perfusion deficits and amyloid burden were congruent in ICH cases
ith probable CAA, therefore demonstrating a distinct imaging pattern
hich may have potential to be used as an important biomarker for the
iagnosis of CAA. Our analysis can help to elucidate the mechanisms of
erivascular amyloid deposition and can support further investigations
or the early assessment of CAA. 
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